Therapeutic possibilities in patients with selective pituitary resistance to thyroid hormones;Posibilidades terapéuticas en la resistencia hipofisaria selectiva a las hormonas tiroideas

Medicina Clinica

Volumn 130, Issue 9, 2008, Pages 345-350

  Iglesias, Pedro ^a   Díez, Juan José ^b  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Central hyperthyroidism; Inappropriate thyrotropin secretion; Pituitary resistance; Thyroid hormones

Indexed keywords

ANXIOLYTIC AGENT; ATENOLOL; DEXTROTHYROXINE; LEVOTHYROXINE; LIOTHYRONINE; THYROID HORMONE; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; THYROXINE;

GENE MUTATION; GOITER; HORMONE RELEASE; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS; HYPOPHYSIS THYROID SYSTEM; REVIEW; THYROID HORMONE METABOLISM; THYROID HORMONE RESISTANCE;

EID: 42049093805     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13117351     Document Type: Review

References (84)

1. Wynne AG, Gharib H, Scheithauer BW, Davis DH, Freeman SL, Horvath E. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med. 1992;92:15-24.
2. Refetoff S. Resistance to thyroid hormone: an historical overview. Thyroid. 1994;4:345-9.
3. Refetoff S. Resistance to thyroid hormone. Curr Ther Endocrinol Metab. 1997;6:132-4.
4. Refetoff S. Resistance to thyrotropin. J Endocrinol Invest. 2003;26:770-9.
5. Beck-Peccoz P, Forloni F, Cortelazzi D, Persani L, Papandreou MJ, Asteria C, et al. Pituitary resistance to thyroid hormones. Horm Res. 1992;38:66-72.
6. Beck-Peccoz P, Persani L, Calebiro D, Bonomi M, Mannavola D, Campi I. Syndromes of hormone resistance in the hypothalamic-pituitary-thyroid axis. Best Pract Res Clin Endocrinol Metab. 2006;20:529-46.
7. McDermott MT, Ridgway EC. Thyroid hormone resistance syndromes. Am J Med. 1993;94:424-32.
8. Olateju TO, Vanderpump MP. Thyroid hormone resistance. Ann Clin Biochem. 2006;43:431-40.
9. Reichlin S. TRH: historical aspects. Ann N Y Acad Sci. 1989;553:1-6.
10. Morley JE. Neuroendocrine control of thyrotropin secretion. Endocr Rev. 1981;2:396-436.
11. Moura EG, Moura CC. Regulation of thyrotropin synthesis and secretion. Arq Bras Endocrinol Metabol. 2004;48:40-52.
12. Brabant G, Ocran K, Ranft U, Von zur MA, Hesch RD. Physiological regulation of thyrotropin. Biochimie. 1989;71:293-301.
13. DeRuyter H, Burman KD, Wartofsky L, Smallridge RC. Thyrotropin secretion in starved rats is enhanced by somatostatin antiserum. Horm Metab Res. 1984;16:92-6.
14. Fliers E, Alkemade A, Wiersinga WM, Swaab DF. Hypothalamic thyroid hormone feedback in health and disease. Prog Brain Res. 2006;153:189-207.
15. Snyder PJ, Utiger RD. Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones. J Clin Invest. 1972;51:2077-84.
16. Abel ED, Kaulbach HC, Campos-Barros A, Ahima RS, Boers ME, Hashimoto K, et al. Novel insight from transgenic mice into thyroid hormone resistance and the regulation of thyrotropin. J Clin Invest. 1999;103:271-9.
17. Woodmansee WW, Gordon DF, Dowding JM, Stolz B, Lloyd RV, James RA, et al. The effect of thyroid hormone and a long-acting somatostatin analogue on TtT-97 murine thyrotropic tumors. Thyroid. 2000;10:533-41.
18. De Rosa G, Corsello SM, Della Casa S, De Rosa E, Raimondo S. Effect of somatostatin on the pituitary-thyroid axis. Ann Endocrinol (Paris). 1983;44:355-60.
19. Sassolas G, Khalfallah Y, Chayvialle JA, Cohen R, Merabet S, Casez JP, et al. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab. 1989;68:239-46.
20. Curty FH, Lisboa PC, Ortiga-Carvalho TM, Pazos-Moura CC. The somatostatin analogue octreotide modulates Iodothyronine deiodinase activity and pituitary neuromedin B. Thyroid. 2000;10:647-52.
21. Reddy S, Bhansali A, Sialy R, Masoodi S, Dutta P, Bhadada S, et al. Dopaminergic influence on thyrotropin secretion in primary hypothyroidism. Horm Metab Res. 2005;37:286-9.
22. Ridgway EC, Greenspan S, Shupnik M. Hypothalamic regulation of thyrotropin biosynthesis and secretion. Horm Metab Res. 1987;17 Suppl:78-82.
23. Alkemade A, Unmehopa UA, Wiersinga WM, Swaab DF, Fliers E. Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J Clin Endocrinol Metab. 2005;90:323-7.
24. Coiro V, Volpi R, Cataldo S, Capretti L, Caffarri G, Pilla S, et al. Dopaminergic and cholinergic involvement in the inhibitory effect of dexamethasone on the TSH response to TRH. J Investig Med. 2000;48:133-6.
25. Coiro V, Volpi R, Capretti L, Speroni G, Pilla S, Cataldo S, et al. Effect of dexamethasone on TSH secretion induced by TRH in human obesity. J Investig Med. 2001;49:330-4.
26. Sap J, Muñoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, et al. The cerb-A protein is a high-affinity receptor for thyroid hormone. Nature. 1986;324:635-40.
27. Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM. The c-erb-A gene encodes a thyroid hormone receptor. Nature. 1986;324:641-6.
28. Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev. 1993;14:184-93.
29. Yen PM. Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab. 2003;14:327-33.
30. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev. 1993;14:348-99.
31. Adams M, Matthews C, Collingwood TN, Tone Y, Beck-Peccoz P, Chatterjee KK. Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene. J Clin Invest. 1994;94:506-15.
32. McDermott MT, Ridgway EC. Central hyperthyroidism. Endocrinol Metab Clin North Am 1998;27:187-203.
33. McDermott JH, Agha A, McMahon M, Gasparro D, Moeller L, Dumitrescu AM, et al. A case of resistance to thyroid hormone without mutation in the thyroid hormone receptor beta. Ir J Med Sci. 2005;174:60-4.
34. Weiss RE, Xu J, Ning G, Pohlenz J, O'Malley BW, Refetoff S. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J. 1999;18:1900-4.
35. Brown NS, Smart A, Sharma V, Brinkmeier ML, Greenlee L, Camper SA, et al. Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse. J Clin Invest. 2000;106:73-9.
36. Gershengorn MC, Weintraub BD. Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of «inappropriate secretion of TSH». J Clin Invest. 1975;56:633-42.
37. Beck-Peccoz P, Mannavola D, Persani L. Syndromes of thyroid hormone resistance. Ann Endocrinol (Paris). 2005;66:264-9.
38. 3 in hyperthyroidism. Clin Endocrinol (Oxf). 1983;18:139-42.
39. Weiss RE, Refetoff S. Resistance to thyroid hormone. Rev Endocr Metab Disord. 2000;1:97-108.
40. Weiss RE, Refetoff S. Thyroid hormone resistance. Annu Rev Med. 1992;43:363-75.
41. Weiss RE, Refetoff S. Treatment of resistance to thyroid hormone - primum non nocere. J Clin Endocrinol Metab. 1999;84:401-4.
42. Faglia G, Beck-Peccoz P, Piscitelli G, Medri G. Inappropriate secretion of thyrotropin by the pituitary. Horm Res. 1987;26:79-99.
43. 3), bromocriptine and Triac on inappropriate TSH hypersecretion. Clin Endocrinol (Oxf). 1988;28:497-507.
44. Beck-Peccoz P, Piscitelli G, Cattaneo MG, Faglia G. Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3′-triiodothyroactic acid (TRIAC). J Endocrinol Invest. 1983;6:217-23.
45. Crino A, Borrelli P, Salvatori R, Cortelazzi D, Roncoroni R, Beck-Peccoz P. Anti-iodothyronine autoantibodies in a girl with hyperthyroidism due to pituitary resistance to thyroid hormones. J Endocrinol Invest. 1992;15: 113-20.
46. Aguilar DM, Escobar-Jiménez L, Fernández Soto ML, García CA, Escobar-Jiménez F. Hyperthyroidism due to familial pituitary resistance to thyroid hormone: successful control with 3, 5, 3′ triiodothyroacetic associated to propranolol. J Endocrinol Invest. 1991;14:663-8.
47. Dulgeroff AJ, Geffner ME, Koyal SN, Wong M, Hershman JM. Bromocriptine and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone. J Clin Endocrinol Metab. 1992;75:1071-5.
48. Kunitake JM, Hartman N, Henson LC, Lieberman J, Williams DE, Wong M, et al. 3,5,3′-triiodothyroacetic acid therapy for thyroid hormone resistance. J Clin Endocrinol Metab. 1989;69:461-6.
49. Hamon P, Bovier-Lapierre M, Robert M, Peynaud D, Pugeat M, Orgiazzi J. Hyperthyroidism due to selective pituitary resistance to thyroid hormones in a 15-month-old boy: efficacy of D-thyroxine therapy. J Clin Endocrinol Metab. 1988;67:1089-93.
50. Medeiros-Neto G, Kallas WG, Knobel M, Cavaliere H, Mattar E. Triac (3,5,3′-triiodothyroacetic acid) partially inhibits the thyrotropin response to synthetic thyrothropin-releasing hormone in normal and thyroidectomized hypothyroid patients. J Clin Endocrinol Metab. 1980;50:223-5.
51. 3 and Triac in the rat: a possible explanation of differential hormone potency. Endocrinology. 1976;98:666-75.
52. Takeda T, Suzuki S, Liu RT, DeGroot LJ. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab. 1995;80:2033-40.
53. 3) and its analogs to the in vitro translational products of c-erb A protooncogenes: differences in the affinity of the α- and β-forms for the acetic acid analog and failure of the human testis and kidney α-2 products to bind T3. Mol Endocrinol. 1990;4:227-34.
54. Asteria C, Rajanayagam O, Collingwood TN, Persani L, Romoli R, Mannavola D, et al. Prenatal diagnosis of thyroid hormone resistance. J Clin Endocrinol Metab. 1999;84:405-10.
55. Ueda S, Takamatsu J, Fukata S, Tanaka K, Shimizu N, Sakata S, et al. Differences in response of thyrotropin to 3,5,3′-triiodothyronine and 3,5,3′-triiodothyroacetic acid in patients with resistance to thyroid hormone. Thyroid. 1996;6:563-70.
56. Gless KH, Oster P, Hufner M. Influence of D-thyroxine on plasma thyroid hormone levels and TSH secretion. Horm Metab Res. 1977;9:69-73.
57. Gorman CA, Jiang NS, Ellsfson RD, Elveback LR. Comparative effectiveness of dextrothyroxine and levothyroxine in correcting hypothyroidism and lowering blood lipid levels in hypothyroid patients. J Clin Endocrinol Metab. 1979;49:1-7.
58. Dorey F, Strauch G, Gayno JP. Thyrotoxicosis due to pituitary resistance to thyroid hormones. Successful control with D thyroxine: a study in three patients. Clin Endocrinol (Oxf). 1990;32:221-8.
59. Krawczynska H, Wojcik-Musialek K, Llig R. 10 years of successful treatment with dextrothyroxine in a girl with TSH-induced hyperthyroidism. Horm Res. 1991;35:213-6.
60. Schwartz ID, Bercu BB. Dextrothyroxine in the treatment of generalized thyroid hormone resistance in a boy homozygous for a defect in the T3 receptor. Thyroid. 1992;2:15-9.
61. Rosler A, Litvin Y, Hage C, Gross J, Cerasi E. Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine. J Clin Endocrinol Metab. 1982;54:76-82.
62. Magee B, Sheridan B, Scanlon MF, Atkinson AB. Inappropriate thyrotrophin secretion, increased dopaminergic tone and preservation of the diurnal rhythm in serum TSH. Clin Endocrinol (Oxf). 1986;24:209-15.
63. Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary. 2002;5:83-8.
64. Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001;86:2849-53.
65. Iglesias P, Díez JJ. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide. J Endocrinol Invest. 1998;21:775-8.
66. Beck-Peccoz P, Mariotti S, Guillausseau PJ, Medri G, Piscitelli G, Bertoli A, et al. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. J Clin Endocrinol Metab. 1989;68:208-14.
67. Shimatsu A, Murabe H, Kamoi K, Suzuki Y, Nakao K. Treatment of thyrotropin-secreting pituitary adenomas with octreotide. Endocr J. 1999;46:113-23.
68. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol. 1994;40:421-8.
69. Gorden P, Comi RJ, Maton PN, Go VL. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989;110:35-50.
70. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med. 1987;317:12-7.
71. Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, et al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf). 2005;62:176-81.
72. Williams G, Kraenzlin M, Sandler L, Burrin J, Law A, Bloom S, et al. Hyperthyroidism due to non-tumoural inappropriate TSH secretion. Effect of a long-acting somatostatin analogue (SMS 201-995). Acta Endocrinol (Copenh). 1986;113:42-6.
73. Ivan G, Szigeti-Csucs N, Olah M, Nagy GM, Goth MI. Treatment of pituitary tumors: dopamine agonists. Endocrine. 2005;28:101-10.
74. Camacho P, Mazzone T. Thyrotropin-secreting pituitary adenoma responsive to bromocriptine therapy. Endocr Pract. 1999;5:257-60.
75. Sriwatanakul K, McCormick K, Woolf P. Thyrotropin (TSH)-induced hyperthyroidism: response of TSH to dopamine and its agonists. J Clin Endocrinol Metab. 1984;58:255-61.
76. Takamatsu J, Mozai T, Kuma K. Bromocriptine therapy for hyperthyroidism due to increased thyrotropin secretion. J Clin Endocrinol Metab. 1984;58:934-6.
77. De Luis DA, Lahera M, Botella MA, Valero C, Varela C. Eficacia de la quinagolida en el tratamiento de un paciente con resistencia hipofisaria a hormonas tiroideas. An Med Interna (Madrid). 2001;18:259-61.
78. Mulinda JR, Hasinski S, Rose LI. Successful therapy for a mixed thyrotropin-and prolactin-secreting pituitary macroadenoma with cabergoline. Endocr Pract 1999;5:76-9.
79. Rivolta CM, Mallea Gil MS, Ballarino C, Ridruejo MC, Miguel CM, Giménez SB, et al. A novel 1297-1304delGCCTGCCA mutation in the exon 10 of the thyroid hormone receptor beta gene causes resistance to thyroid hormone. Mol Diagn. 2004;8:163-9.
80. Samuels MH, McDaniel PA. Thyrotropin levels during hydrocortisone infusions that mimic fasting-induced cortisol elevations: a clinical research center study. J Clin Endocrinol Metab. 1997;82:3700-4.
81. Brabant A, Brabant G, Schuermeyer T, Ranft U, Schmidt FW, Hesch RD, et al. The role of glucocorticoids in the regulation of thyrotropin. Acta Endocrinol (Copenh). 1989;121:95-100.
82. Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest. 1969;48:2096-103.
83. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999;340:1075-9.
84. Golden WM, Weber KB, Hernández TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007;92:124-30.